Clobetasol propionate
- Generic Name
- Clobetasol propionate
- Brand Names
- Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32ClFO5
- CAS Number
- 25122-46-7
- Unique Ingredient Identifier
- 779619577M
- Background
Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the literature in 1974.
Clobetasol Propionate was granted FDA approval on 27 December 1985.
- Indication
Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
- Associated Conditions
- Alopecia, Severe Plaque psoriasis, Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis, Moderate Plaque psoriasis, Moderate Scalp Psoriasis, Severe Scalp Psoriasis
- Associated Therapies
- -
Formosa gets rights to Medvisis' treatment for pain after ocular surgery
Formosa Pharmaceuticals signs exclusive deal with Medvisis Switzerland to market APP13007, a clobetasol propionate ophthalmic suspension for post-operative inflammation and pain after ocular surgery. The FDA-approved treatment, based on Formosa's APNT nanoparticle platform, offers twice-daily dosing for 14 days. The agreement includes upfront payment and sales milestones, aiming to benefit Swiss patients with faster symptom relief.
Eyenovia Provides Update on Phase 3 CHAPERONE Study
Eyenovia's CHAPERONE Phase 3 study fails to meet primary endpoint of less than 0.5 diopter progression in visual acuity over three years. The independent Data Review Committee found no significant difference in myopia progression between treatment arms and placebo. Eyenovia plans to discontinue the study, review data, and evaluate next steps.
Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase ...
Formosa Pharmaceuticals reports successful Phase 3 results for APP13007 in Chinese cataract surgery patients, achieving rapid and sustained resolution of inflammation and pain, with a safety profile similar to placebo.
More companies share upcoming AAO presentation information
The 2024 American Academy of Ophthalmology meeting in Chicago will feature presentations on clinical trial data from Alkeus Pharmaceuticals, Annexon, Inc., Atsena Therapeutics, Avirmax Biopharma, Inc., Beacon Therapeutics, Belite Bio, Eyenovia, LENZ Therapeutics, Nanoscope Therapeutics, Inc., and ZEISS Medical Technology.
EYEN Shares Are Trading Higher Today: What You Need To Know
Eyenovia Inc (EYEN) shares surge due to the launch of FDA-approved ophthalmic drug APP13007, developed with Formosa Pharmaceuticals. The drug, using clobetasol propionate, treats postoperative inflammation and pain, with a twice-daily dosing regimen. Formosa has shipped the drug for U.S. commercialization, with Eyenovia set to begin full-scale commercialization in September 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath